Related Experiment Videos
Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal
Insights
Patients with high levels of anticardiolipin antibodies, linked to lupus anticoagulant, may face recurrent thrombosis after stopping warfarin. Long-term anticoagulation is recommended to prevent blood clots in these individuals.
Area of Science:
- Immunology
- Hematology
Background:
- Anticardiolipin antibodies are associated with thrombosis and lupus anticoagulant.
- Understanding the role of these antibodies in recurrent vascular events is crucial.
Observation:
- Six patients with high anticardiolipin antibody titers experienced recurrent vascular occlusions 6-12 weeks post-warfarin withdrawal.
- Observed events included deep vein thrombosis and myocardial infarction.
Findings:
- Warfarin withdrawal in patients with high anticardiolipin antibodies can precipitate recurrent thrombosis.
- A significant risk of vascular occlusion exists following cessation of anticoagulation.
Implications:
- Long-term anticoagulation is advised for patients with high anticardiolipin antibody levels to minimize thrombosis risk.
- Monitoring antibody levels and managing anticoagulation strategies are critical for patient outcomes.
Abstract:
Antibodies to cardiolipin, closely related to the 'lupus anticoagulant', are strongly implicated in the pathogenesis of thrombosis. We record six patients, all with high titres of these antibodies (greater than SD) in serum, who developed recurrent vascular occlusions six to 12 weeks after warfarin withdrawal. Five of the six had deep vein thrombosis, while the sixth suffered a myocardial infarction. To minimise the risk of 'recurrent' thrombosis it is strongly suggested that such patients remain on long-term anticoagulation, pending the reduction of high antibody levels.